Business Context and Reporting Period
Lifecore Biomedical, Inc. is a single-segment contract development and manufacturing organization providing development, aseptic fill-finish, and manufacturing services for sterile injectable products, including hyaluronic acid products. The Company exited its former food businesses, which are reported as discontinued operations.
This Form 10-Q covers the fiscal quarter and six months ended November 26, 2023, compared with the restated periods ended November 27, 2022. The filing was signed on August 9, 2024, and the cover states that the Company had not filed all required reports during the preceding 12 months.
Key Financial Metrics
| Metric | Three Months Ended November 26, 2023 | Prior Year | Six Months Ended November 26, 2023 | Prior Year |
|---|---|---|---|---|
| Total revenue | $30.2 million | $21.9 million | $54.7 million | $45.6 million |
| Gross profit | $10.0 million | $5.7 million | $12.7 million | $11.7 million |
| Gross margin | 33.0% | 26.0% | 23.2% | 25.6% |
| Operating loss | $(1.5) million | $(5.4) million | $(10.1) million | $(8.6) million |
| Net income (loss) | $14.2 million | $(12.8) million | $3.5 million | $(23.8) million |
| Adjusted EBITDA | $5.4 million | $1.5 million | $3.4 million | $2.8 million |
Quarterly CDMO revenue increased to $23.7 million from $16.2 million, while HA manufacturing revenue increased to $6.5 million from $5.7 million. Related-party revenue, primarily associated with Alcon, was $9.6 million for the quarter and $17.2 million for the six-month period.
Quarterly net income was materially affected by a $20.7 million non-cash gain from the decrease in the fair value of the related-party debt derivative liability. For the six-month period, the corresponding gain was $20.9 million. Excluding this item, reported profitability was substantially weaker than headline net income suggests.
- Cash declined to $3.2 million at November 26, 2023 from $19.1 million at May 28, 2023.
- Operating cash flow was $(7.3) million for the six months, compared with $(3.5) million in the prior-year period.
- Capital expenditures were $9.0 million, primarily for equipment supporting growth.
- Total current assets were $76.7 million versus current liabilities of $40.3 million; liquidity included approximately $9.1 million of revolver availability.
- Term-loan borrowings were $149.7 million at a stated effective annual rate of 10.0%; revolver borrowings were $16.9 million at 10.18%.
- The term loan matures May 22, 2029. The debt derivative liability was $44.0 million, down from $64.9 million at May 28, 2023.
- Convertible preferred stock had a carrying value of $40.9 million and accrued paid-in-kind dividends during the period.
Material Changes Versus the Prior Comparable Period
- Revenue increased 38% for the quarter and 20% for the six-month period, driven primarily by higher CDMO demand. Fermentation revenue benefited from shipment timing in the quarter but declined for the six-month period.
- Quarterly gross margin improved by 705 basis points to 33.0%, primarily from favorable CDMO mix and volume. Six-month gross margin declined by 237 basis points to 23.2%, reflecting lower development revenue, unfavorable mix, and lower fermentation revenue.
- SG&A increased 11% for the quarter and 12% for the six-month period, driven by personnel, consulting, audit, and stock-based compensation costs.
- Operating losses improved in the quarter but widened for the six-month period. Prior-year results included a $2.1 million gain on the sale of the BreatheWay business and higher restructuring costs.
- The Company refinanced its prior term loan with Alcon on May 22, 2023. The financing cured prior debt covenant noncompliance but created substantial related-party debt, interest expense, and a complex Level 3 derivative liability.
- The Company recorded $6.4 million of related-party interest expense for the six-month period, including $6.2 million of interest paid in kind.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing does not provide clear quantitative revenue, earnings, or cash-flow guidance. Management stated that existing cash, operating cash flow, and revolver availability were expected to fund operations and capital requirements for at least the next twelve months, but also noted that additional funding may be required if internally generated cash is insufficient.
- Internal controls: Disclosure controls were deemed ineffective at period-end because of material weaknesses in internal control over financial reporting. Remediation efforts include third-party assistance, additional finance personnel, enhanced review controls, SOX governance, and expanded internal audit work.
- Restatement and SEC inquiry: Prior quarterly financial statements were restated. The SEC issued a subpoena on February 16, 2024 seeking information concerning the restatement; the Company is cooperating and cannot predict the outcome.
- Debt and covenant risk: The Company entered into limited waivers and amendments with Alcon and BMO after the reporting date relating to specified defaults, historical financial statements, reporting deadlines, and other credit terms.
- Customer concentration: Three customers represented 32%, 22%, and 22% of quarterly sales; three customers represented 31%, 22%, and 14% of six-month sales. Alcon is both a major customer and a principal lender.
- Supply agreements: A customer supply agreement was amended after period-end, including a $5.0 million working-capital deposit and later extension through December 31, 2026. A separate amended Alcon manufacturing agreement runs initially through December 31, 2031 but includes performance requirements and termination rights.
- Legal matters: The Company disclosed landlord claims involving approximately $0.2 million and $0.1 million of alleged past-due rent, a shareholder class action filed in July 2024, and other ordinary-course contingencies. Potential loss from the class action was not considered probable or estimable.
- Strategic and restructuring actions: The Company later assigned substantially all assets of certain former food-business entities for liquidation and announced a workforce reduction of 46 employees, estimated to cost approximately $1.0 million.
- Non-GAAP results: Adjusted EBITDA excludes, among other items, derivative fair-value changes, restructuring, reorganization, financing, start-up, contract-cancellation, and stock-based compensation costs. These adjustments are significant and limit comparability with GAAP earnings.
Most Important Facts for Investors to Verify
- Whether the Company can generate positive operating cash flow while funding planned capital expenditures and servicing high-cost debt.
- The remaining availability, borrowing-base limitations, covenant requirements, and waiver status under the Alcon term loan and BMO revolver.
- The sustainability of revenue growth and the quarterly gross-margin improvement, particularly given customer concentration and shipment timing.
- The economic impact and potential volatility of the $44.0 million Level 3 debt derivative liability and related non-cash gains.
- The status and effectiveness of remediation for the material weaknesses and the implications of the SEC subpoena and prior restatement.
- The terms, pricing, minimum purchase obligations, performance metrics, and termination rights in the amended customer and Alcon agreements.
- The potential dilution and redemption economics of the $40.9 million convertible preferred stock, including paid-in-kind dividends and conversion rights.
- The outcome and potential exposure from the shareholder class action, landlord claims, divestiture-related obligations, and other contingent liabilities.